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Abstract
Machine perfusion-based organ preservation techniques are prudently transitioning into clinical 
practice. Although experimental data is compelling, the outcomes in the highly variable clinical 
donation-transplantation setting are unpredictable. Here, we offer an intermediate tool for pre-
clinical assessment of human donor livers. We present a model for ex situ reperfusion of discarded 
human livers and report on its application in three human livers that have undergone 
subnormothermic (21°C) machine perfusion as an experimental preservation method. During 
reperfusion, the livers macroscopically reperfused in the first 15 minutes, and remained visually 
well-perfused for 3 hours of ex situ reperfusion. Bile production and oxygen consumption were 
observed throughout ex situ reperfusion. ATP levels increased 4.25-fold during SNMP. Between 
the end of SNMP and the end of reperfusion ATP levels dropped 45%. ALT levels in blood 
increased rapidly in the first 30 minutes and ALT release continued to taper off towards the end of 
perfusion. Release of CRP, TNF-α, IL-1β, and IL-12, IFN-γ was sustained during reperfusion. 
These findings support the use of this model for the evaluation of novel human liver preservation 
techniques.
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Novel organ preservation methods have been studied in numerous models to date, including 
animal and discarded human organ models. Discarded human organs have proven useful in 
establishing proof of concept, however no models exist that provide a useful pre-clinical 
representation of reperfusion of the human organ. As novel organ preservation techniques 
are developed towards clinical studies, a pre-clinical human reperfusion model would enable 
evaluation of the technique in the uncontrolled setting of human organ donation. Moreover, a 
human organ reperfusion model would reveal unanticipated outcomes following reperfusion 
of inherently variable human organs, prior to translation from animal models to clinical 
studies. In this study, we report on a novel model of ex situ reperfusion of the discarded 
human liver, using diluted whole blood sourced from the liver donor. To our knowledge this 
is the first study that uses a simulated reperfusion to evaluate human livers following 
experimental preservation.
INTRODUCTION
Alternatives to static cold storage (SCS) of the liver have received significant interest as a 
means of expanding the currently limited donor organ pool. Machine perfusion (MP) 
techniques, in particular, have developed rapidly and are prudently being translated to 
clinical application1. These techniques aim to improve the preservation of the liver by 
offering a more supportive environment by providing a continuous flow of oxygen and 
nutrients through the organ, from hypothermic, to normothermic temperatures, including 
subnormothermic machine perfusion (SNMP)2. In animal models, benefits of MP have been 
shown over the full temperature spectrum. In these models, superiority over conventional 
SCS has been demonstrated using orthotopic transplantation3–5 or a simulated reperfusion 
ex situ6–8. For a number of reasons clinical translation of these models should proceed 
prudently. Firstly, the controlled experimental environment is not representative of the true 
logistics of transplantation. Secondly, variability in human livers is sizeable and 
unpredictable. While experimental models are an adequate representation of a healthy organ, 
machine perfusion following the combination of donor factors (steatosis, age, nutritional 
status) as well as procurement factors (surgical technique, warm- and cold ischemia time, 
flush) may prove erratic when transitioning to the clinical application9. For this reason, we 
and other groups have performed MP of discarded grafts to learn the specific dynamics of 
human liver perfusion10‘11. This provides insight into human liver function and injury 
during perfusion preservation, but omits valuable information on the effect on the graft after 
reperfusion and fails to completely capture ischemia/reperfusion injury (IRI). To date, no 
pre-clinical models for reperfusion of the human liver after machine perfusion preservation 
have been described. Herein, we present a procedure to model reperfusion ex situ using 
diluted autologous whole blood, which was conceptually and logistically tested using 
discarded human livers donated after cardiac death and preserved by SNMP.
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Discarded human livers were used for testing of the experimental model (n = 3). All grafts 
were donated after cardiac death (DCD), and were procured in the New England Donor 
Services (NEDS) region with consent from the donor’s family for research use. Grafts were 
rejected for transplantation due to DCD status in combination with donor age (n = 2) or 
macrovesicular steatosis (n = 1). Livers were procured following standard procurement 
procedures for transplantation, described in more detail elsewhere12. Autologous blood was 
collected simultaneously with organ procurement, as described below. Liver and blood were 
packaged on ice and transported to our setting, while the SNMP was prepared. Target cold 
ischemia time, measured between cold flush and connection to the perfusion device was 240 
minutes.
The Massachusetts General Hospital Institutional Review Board (IRB) and the New England 
Donor Services (NEDS) approved this study (No. 2011P001496) and all studies were carried 
out in accordance with IRB and NEDS approved guidelines.
Autologous blood collection and processing
Suction canisters used perioperatively for blood drainage were primed with 104 U of sodium 
heparin. Blood was collected following transection of the vena cava, and during the cold 
flush of the organs. Six liters of blood combined with University of Wisconsin solution 
could generally be collected. On arrival at our center, blood was processed to produce a 
clean cell concentrate. The solution was first filtered through a 90-pm mesh and 
subsequently centrifuged at 2,400 rpm. The erythrocyte and leukocyte layers were washed 
twice in 10% dextrose in 0.9% NaCl solution. A final hematocrit of 21% was achieved using 
type-matched fresh frozen plasma (FFP). The final volume of 1.5 L was finally 
supplemented with 100 U of insulin (Humulin), an additional 2,000 units of sodiumheparin, 
ceftriaxone 1 g/L. The pH was corrected to 7.30–7.50 using sodiumbicarbonate 8.4%.
Subnormothermic machine perfusion
Subnormothermic machine perfusion was performed following the concepts and methods 
described elsewhere11, with the difference in the use of a commercial MP device (Liver 
Assist, Organ Assist B.V., Groningen, The Netherlands). Briefly, this involves 3 hours of MP 
at 21°C using oxygenated (95% O2/5 CO2) Williams’ Medium E, perfusing the liver through 
the portal vein and hepatic artery at set pressures of 3 and 30 mmHg, respectively.
Ex situ autologous whole-blood reperfusion
Following machine perfusion, the liver was cold flushed with ice-cold Lactated Ringers 
(LR) solution over a period of 20 minutes to reflect sewing-in time. During this time the 
device was primed for reperfusion with the diluted whole-blood and set to 37°C. 
Oxygenators were gassed with 95% O2/5% CO2 and blood was sampled for adequate pH 
(7.3−7.5) and oxygenation. The liver was then connected to the MP system and pressure on 
the portal vein and hepatic artery were set to 6 mmHg and 60 mmHg, respectively, matching 
hemodynamics seen intraoperatively13. Reperfusion was continued for three hours, while 
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perfusion measurements were recorded and blood and tissue samples were taken and stored 
at −80°C before further analysis. Blood gas analysis was performed using a benchtop 
bloodgas analyzer (Rapidpoint 500, Siemens). Oxygen consumption was calculated from the 
difference between in and outflow dissolved and hemoglobin-bound oxygen content.
Functional and injury assessment
Alanine transaminase (ALT) release was determined in the blood using a point-of-care blood 
chemistry analyzer (Piccolo, Abaxis, Union City, CA). Levels of C-reactive protein (CRP), 
TNF- α, IL-1β, IFN-γ and IL-12 were determined in the blood using a multiplex bead array 
(Eve Technologies, Calgary, Canada). Absolute concentration of adenosine triphosphate 
(ATP) was measured in liver samples using a luminescence-based assay (Cell Viability Kit; 
Biovision). Nucleotides were extracted from ~1 mg of homogenized tissue, after which peak 
luminescence was determined. ATP concentrations were normalized to tissue protein using a 
BCA protein assay (Thermo Fisher Scientific, Waltham, MA).
RESULTS
Using the technical steps of organ procurement, preparation of the autologous whole blood 
and the liver, and priming of the machine perfusion device, we were successful in achieving 
a reproducible model of reperfusion. Collection of the blood from the organ donor reliably 
provided the required 1.5 L of diluted whole blood (21% hematocrit). Using this machine 
perfusion device, flow during SNMP was consistent with what has been previously observed 
with a different device (Fig. 1)11. Following SNMP and 20 minutes of cold-flush with LR 
solution, the livers were successfully reconnected to the blood-primed device for 
reperfusion.
Ex situ autologous whole-blood reperfusion
The livers macroscopically reperfused during the first 15 minutes, and remained visually 
well-perfused during the 3 hours of ex situ reperfusion (Fig. 2a). Flow in the portal vein was 
an average of 0.37 ± 0.16 mL/min.g liver in the first 10 minutes and gradually increased and 
plateaued at an average of 0.79 ± 0.16 mL/min.g liver at three hours (Fig. 2b). Bile 
production began nearly immediately in all cases and continued to flow constantly at an 
average rate of 7.0 mL/h throughout (Fig. 2c). Oxygen uptake, calculated from the 
difference in inflow and outflow dissolved and Hb-bound O2, remained fairly consistent 
during reperfusion (~ 20 mL O2/min.kg liver) (Fig. 2d). ATP levels increased 4.25-fold 
during SNMP (Fig. 3). Between the end of SNMP and the end of reperfusion ATP levels 
dropped 45%, from 3.64 ± 1.11 to 2.51 ± 0.262 nmol mg protein−1. ALT concentrations in 
blood increased most rapidly in the first 30 minutes of reperfusion and ALT release 
continued to taper off until the end of reperfusion (Fig. 4a). Average ALT release into the 
blood at the end of reperfusion was 1155 ± 225 IU/L. Release of CRP, TNF-a, IL-1p, and 
IL-12, IFN-y was sustained during reperfusion (Fig. 4b–f).
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Herein we present a methodology to model reperfusion of the human liver ex situ as a means 
to model IRI and study novel liver preservation techniques. Various liver machine perfusion 
techniques are currently transitioning into clinical application, including the first 
normothermic perfusion preservation modalities14,15. This translation is backed by 
preclinical reports in experimental models, which have proven promising by showing 
improved results after orthotopic transplantation in animal models using machine perfusion-
based preservation techniques5,16. While these studies provide basic evidence for feasibility 
of the techniques, they do not factor in the complexities and unpredictability of human liver 
donation and transplantation. For instance, the logistics of human organ transplantation, 
including transport and timing, is far more complex than in a controlled experimental 
setting. Moreover, human livers exhibit a tremendous variation in organ characteristics9, 
which can lead to unanticipated results when attempting to transplant these organs after 
machine perfusion. To this end we provide an experimental tool for pre-clinical modeling of 
reperfusion in human livers.
In stead of orthotopic transplantation, various experimental reports have used a simulated ex 
situ reperfusion in animal models6–8. Donor blood is collected and used in an ex situ 
normothermic perfusion set-up to model reperfusion instead of transplanting the liver. While 
this method does not fully capture the transplantation process, it has the advantage of being 
more controlled than transplantation as well as being more conducive to measurements, 
including flow dynamics, bile production and histological sampling. We have shown 
previously that diluted whole blood reperfusion accurately models reperfusion and analysis 
of leaked transaminases during simulated ex situ are predictive of actual transplant 
outcome17.
To our knowledge report is the first ex situ reperfusion of a human liver following machine 
perfusion as a preservation method. Using whole human blood is complicated by the 
availability of human blood for experimental purposes. To overcome this, we procured 
autologous blood from the organ donor concurrent with the organ procurement. The use of 
autologous blood omits immunological responses of allogeneic transplantation, which is rare 
and arguably negligible in ABO-compatible liver transplants. The presence of leukocytes in 
the blood does however retain reperfusion-induced inflammatory response, which is more 
prominent in the early stages of transplantation. Moreover, consistently using blood from the 
organ donor improves uniformity between reperfusions. We are uninformed, however, of 
what effects heterologous blood would have on the parameters studied and this should be 
taken into consideration. In addition, the extensive manipulation of the blood may result in 
activation or alteration of the function of present immunocompetent cells.
The technical steps outlined here to procure blood from the liver donor consistently enabled 
us to produce the required amount of diluted whole blood, with a target hematocrit of 21%, 
which was achieved using unused FFP from our institution’s blood bank. The reperfusion 
was performed on a commercial liver perfusion device, which is designed for a full-range of 
temperatures. Our results using three discarded human livers show a homogeneous 
reperfusion of the organ and a consistent flow through both the hepatic artery and portal vein 
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following the initial reperfusion and rewarming of the graft. Moreover, bile production and 
oxygen uptake were stable during the three hours of simulated reperfusion, demonstrating 
the stability of the system.
In various reports we have emphasized the importance of energy metabolism for transplant 
outcome4,9,11,12,18 We present the ATP levels at various stages of the perfusion-reperfusion 
process and reiterate the stark increase we have seen after SNMP of both cold and warm 
ischemic livers4,19. Interestingly, 3 hours of reperfusion of the livers following SNMP is not 
able to restore ATP levels to those seen after SNMP. We explain this by a likely significant 
drop in ATP during the modeled ‘sewing in’ time, during which the liver is ischemic, as well 
as the injurious effects of reperfusion attenuating energetic recovery. The relatively short 
reperfusion period does not allow for interrogation of ATP levels later in the reperfusion 
process, nor the later stages of IRI. We report on the release of injury markers here and show 
a sustained release of ALT and CRP as well as various inflammatory cytokines, which is 
expected during reperfusion after MP20. It is important to note that the livers studied here 
were found to be of insufficient quality for use in transplantation, and that machine perfusion 
and simulated reperfusion of higher quality livers may give different results.
In conclusion, this report outlines for the first time a procedure for simulated reperfusion of 
the human liver using autologous whole-blood obtained from the organ donor, which was 
evaluated in discarded human livers preserved by SNMP. The experimental technique offers 
a pre-clinical tool for assessing human livers, facilitating the translation of machine 
perfusion-based liver preservation into clinical practice.
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Figure 1. Perfusion dynamics during SNMP.
Flow rates during SNMP as measured on the portal vein and hepatic artery. Lines represent 
individual livers.
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Figure 2. Reperfusion dynamics during simulated reperfusion.
Representative images of ex situ reperfusion of a human liver following preservation by 
subnormothermic machine perfusion (a), flow through the hepatic artery (HA) and portal 
vein (PV) during reperfusion (b), cumulative production of bile during reperfusion (c) and 
oxygen uptake from hemoglobin-bound and dissolved oxygen (d). Data is presented as an 
individual line per liver.
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Figure 3. Liver tissue ATP content at various stages of preservation and reperfusion.
ATP content at the end of ~4 hours of static cold storage (SCS), at the end of 
subnormothermic machine perfusion (SNMP), and at the end of simulated reperfusion (RP). 
Bars represent mean + SE. Not significant; 2-way ANOVA.
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Figure 4. Markers of injury and inflammation during simulated reperfusion.
Levels of alanine transaminase (ALT) (a), C-reactive protein (CRP) (b), and inflammatory 
cytokines; IFN-γ (c), TNF-α (d), IL-12 (e) and IL-1β (f) measured in blood. Data 
presented as mean + SE.
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Table 1
Discarded human liver donor characteristics.
Age Sex Type CIT Donor WIT HCV Donor COD Liver weight (g)
1 63 M DCD 259 24 - Head trauma 1840
2 33 M DCD 254 13 - Anoxia 2430
3 58 F DCD 291 27 - Head trauma 1620
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